~~<i id='1CA31D7943'><strike id='1CA31D7943'><tt id='1CA31D7943'><pre id='1CA31D7943'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：comprehensive 2025-10-02 14:39:20 - browse：65339

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Second xenotransplant done with gene

hotspot

focus

hotspot

focus

Wikipedia

AlastairGrant/APLONDON—AstraZenecasaidFridayanexperimentaldrugtampeddowntheprogressionofacertaintype

WSS

Intarcia’s device

Lasker Awards 2023: Winners in biomedical research

Lasker Awards 2023: Winners in biomedical research

U.K. decision on ALS drug has neurologists, advocates up in arms

Trial using CRISPR to edit HIV out of cells disappoints

First Opinion on colorectal cancer screening: letter and response

hotspot

focus

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Lasker Awards 2023: Winners in biomedical research

Bright Health sells Medicare Advantage business to Molina

Bird flu in dairy cattle: New measures to control spread to humans

Medicare details structure of new drug price negotiation program

Medicare Advantage 2025 payments will dip, Biden administration says

The cancer drug shortage isn’t new — and neither are the solutions

Trial using CRISPR to edit HIV out of cells disappoints

Trump demands the U.S. pay no more for drugs than other countries … again

Covid silver lining: Unprecedented look at human immune system

hotspot

Biotech stock slump in 2023: awaiting the turnaround

Hundreds died while taking an arthritis drug, but nobody alerted patients

Mass General Brigham physicians react to latest merger step

Covid silver lining: Unprecedented look at human immune system

How Vertex's cystic fibrosis drug is changing patients' lives

Study: Black kids more likely to die after surgery than white kids

focus

hotspot

focus

Wikipedia